BNET Industries
Alexion Pharmaceuticals Inc. (ALXN) is in the Pharma Industry
- Revenue
- Dec 31 2007
- $72.0M
- Profit
- Dec 31 2007
- ($92.2M)
- Market Cap
- Aug 27 2008
- $3.4B
Latest News and Analysis
5 Potential Buyout Targets in Biotech - Barron's
Bristol-Myers Squibb BMY made a $4.5B bid for the shares of ImClone IMCL it doesn't already own. Roche Holdings (RHHBY.PK) made a $44B offer for the shares of Genetech DNA it doesn't own. Both targets want the bid prices raised. Barron's Lawrence Strauss says these are just the two latest...
Alexion Pharmaceuticals, Inc. Q2 2008 Earnings Call
Alexion Pharmaceuticals, Inc. ALXN Q2 FY08 Earnings Call
Alexion Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Alexion Pharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Alexion Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Alexion Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript
Additional Resources
BellwetherReport.com Analyst Report on EVVV, BEAV, ELNK and ALXN
BellwetherReport.com is the leading onlinefinancial newsletter for investors seeking top independent and unbiasedresearch. Investors seeking free and unbiased analyst opinions on thecompanies mentioned in this release are encouraged to sign up to www.bellwetherreport.com for a free subscription to access these reports.Today, we have once again scheduled interviews with a...
InCode BioPharmaceutics, Inc. Announces Key Data Supporting New Treatment of Paroxysmal Nocturnal Hemoglobinuria
SAN FRANCISCO, July 23 /PRNewswire/ -- InCode BioPharmaceutics, Inc., an emerging biopharmaceutical company, today announced preclinical test results demonstrating the utility of their lead drug candidate rC3-1 for the treatment of the rare chronic blood disorder paroxysmal nocturnal hemoglobinuria PNH. The complete results will be presented at the XXII...
Zacks Analyst Blog Highlights: Corel Corporation, Alexion Pharmaceuticals, Proctor & Gamble, Lexicon Pharmaceuticals Inc. and American Public Education, Inc
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Corel Corporation (Nasdaq: CREL), Alexion Pharmaceuticals (Nasdaq: ALXN),...
Alexion to Present at the Jefferies & Co. 2nd Annual Healthcare Conference
CHESHIRE, Conn., June 18 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Jefferies & Co. 2nd Annual Healthcare Conference in New York City at 4:15 p.m., ET on Wednesday, June 25, 2008....
Mergent, Inc. Announces Quarterly Rebalancing of HealthShares™ Indexes
NEW YORK, June 17 /PRNewswire/ -- Mergent, Inc., administrator for the HealthSharesTM Indexes, a series of 20 underlying indexes for the HealthSharesTM Exchange Traded Funds, today announced the quarterly rebalancing of the Indexes. The following securities will be added and deleted in the Indexes effective before...
Soliris® Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
Data Suggest Role of Hemolysis in PNH-Related Fatigue Presentation at the European Hematology Association 13th Congress CHESHIRE, Conn., June 15 /PRNewswire-FirstCall/ -- SolirisR eculizumab therapy improved the often disabling fatigue experienced by patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria PNH...
Alexion to Present at the William Blair 28th Annual Growth Stock Conference
CHESHIRE, Conn., June 13 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Vikas Sinha, Senior Vice President and Chief Financial Officer of Alexion Pharmaceuticals, will present at the William Blair 28th Annual Growth Stock Conference in Chicago at 9:10 a.m., local time (10:10 a.m., eastern)...
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc
Combined Company to Drive Stockholder Value with Commitment to Molecular Chaperone Technology Platform and Near-Term Commercialization Opportunities in Oncology Acquisition Subject to Customary Closing Conditions Including Innovive Stockholder Approval Company to Host Conference Call at 9:00 AM EDT (6:00 AM PDT) Today to...
Alexion to Present at the Goldman Sachs 29th Annual Global Healthcare Conference
CHESHIRE, Conn., June 5 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Goldman Sachs 29th Annual Global Healthcare Conference in Laguna Niguel, CA at 8:00 a.m., local time (11:00 a.m., eastern) on...
Alexion to Present at Citi's 2008 Healthcare Conference
CHESHIRE, Conn., May 14 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at Citi's 2008 Healthcare Conference in New York City at 4:00 p.m. ET on Wednesday, May 21, 2008. An audio webcast of Dr....
Notice of Time Change for Alexion's Presentation at the Bank of America 2008 Health Care Conference
CHESHIRE, Conn., May 9 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that the time of Alexion's presentation at the Bank of America 2008 Health Care Conference in Las Vegas has been changed to 4:00 p.m., local time (7:00 p.m., eastern) on Tuesday, May 13, 2008. Vikas Sinha,...
Alexion to Present at the Bank of America 2008 Health Care Conference
CHESHIRE, Conn., May 6 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Vikas Sinha, Senior Vice President and Chief Financial Officer of Alexion Pharmaceuticals, will present at the Bank of America 2008 Health Care Conference in Las Vegas at 4:40 p.m., local time (7:40 p.m., eastern) on Tuesday,...
Alexion Pharmaceutical Hopes the Fourth Time Is a Charm for Smithfield Site, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial InfoResources (Sugar Land, Texas) -- The most recent incarnation of the formerDowpharma (NYSE:DOW) (Midland, Michigan) plant in Smithfield, RhodeIsland, is now complete. Alexion Pharmaceuticals (NASDAQ:ALXN) (Cheshire,Connecticut) has made a capital investment of $80 million into renovatingthe 60,000-square-foot plant for the production of its blood disorder...
Zacks Analyst Blog Highlights: Oplink Communications, Tellabs, Comtech Group, Terex Corp. and Alexion Pharma
CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Oplink Communications Inc. (Nasdaq: OPLK), Tellabs Inc. (Nasdaq: TLAB), Comtech Group,...
Alexion Pharmaceuticals Inc. Review in Progress.
M2 PRESSWIRE-20 March 2008-The Maybach Review: Alexion Pharmaceuticals Inc. Review in ProgressC1994-2008 M2 COMMUNICATIONS LTD RDATE:20032008 MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Investors wanting to know the truth about...
Alexion to Present at Investor Conferences
CHESHIRE, Conn., March 11 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that Leonard Bell, M.D., Chief Executive Officer of Alexion Pharmaceuticals, will present at two upcoming investor conferences, one sponsored by Cowen and Company and the other by Lehman Brothers. Dr. Bell will present at the...
- Next »
- page 1 of 1
- « Previous
Sort byClose
View by Content TypeClose
View Related Content by Tag Close
- Incorporated: 1992
- CEO: Dr. Leonard Bell M.D
- Employees: 434
Alexion Pharmaceuticals is engaged in the discovery and development of therapeutic products aimed at treating patients with an array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Co. devotes substantially all of its resources to drug discovery, research, and product and clinical development. Co. focuses its product development programs on anti-inflammatory therapeutics. Co.'s product candidate includes Soliris? (eculizumab), for the treatment of a rare, life-threatening blood disorder known as Paroxysmal Nocturnal Hemoglobinuria (PNH), Eculizumab (nebulized), Eculizumab (Intravitreal), CD200 Mab, and DC-SIGN Mab.
Key Competitors
Alexion Pharmaceuticals Inc. Company Info
Board of Directors
Dr. Max Link Ph.D.
Chairman
Dr. Leonard Bell M.D
Mr. David W. Keiser
Dr. Joseph A. Madri Ph.D., M
Mr. Larry L. Mathis
Mr. R. Douglas Norby
Mr. Alvin S. Parven
Dr. Ruedi E. Waeger Ph.D.
Contact Information
352 Knotter Drive
Cheshire, CT
203 272-2596